Abiomed, Inc. (NASDAQ: ABMD) today announced that the underwriters of its recent common stock offering have partially exercised their over-allotment option and purchased 80,068 additional shares of Abiomed common stock from the company. The over-allotment option was granted to the underwriters in connection with the offering of 5,000,000 shares of Abiomed common stock.

After giving effect to the closing of the sale of 80,068 shares resulting from the partial exercise of the over-allotment option, Abiomed has approximately 32,336,501 shares of common stock issued and outstanding. The net proceeds to Abiomed from the exercise of the over-allotment option was approximately $1.0 million, after deducting underwriting discounts and commissions and estimated offering expenses.

The offering was managed by Morgan Stanley & Co. Incorporated and UBS Securities LLC as joint book-running managers.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities. The offering of shares of common stock may be made only by means of a prospectus supplement and the accompanying prospectus. Copies of the final prospectus supplement and the accompanying prospectus can be obtained by contacting the Prospectus Department of: Morgan Stanley, 180 Varick Street, New York, NY, 10004, or by email at prospectus@morganstanley.com; or UBS Investment Bank, 299 Park, New York, NY,10171, (212) 821-3000.

ABOUT ABIOMED

Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery. Our products are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping of the heart. For additional information please visit: www.abiomed.com.